Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference
Press Release – Oslo, Norway, September 17, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that international multicenter Phase III clinical trial data for its non-surgical treatment for cervical HSIL (High-Grade Squamous Intraepithelial Lesion) product candidate Cevira[® ](APL-1702) have been accepted for oral presentation by the International Photodynamic Therapy & Photodiagnosis Update Conference in Germany on September 17, 2024, focusing on the efficacy data related to the regression of